ABSTRACT-The effects of [1] [2] 
yl] amino] ethyl] 2 imidazolidinylidene} propanedinitrile fumarate, is a ranitidine derivative devoid of histamine H2-receptor blocking activity. KW-5092 possesses acetyl choline esterase inhibitory activity and exhibits potentiat ing action on electrically evoked contractions of the isolat ed guinea pig ileum (1) . Furthermore, KW-5092 enhances motility of the gastric antrum and colon in anesthetized rabbits (1) , suggesting that KW-5092 stimulates motility of the alimentary tract in general. Colonic transport activ ity can be estimated by measuring the time required to ex crete a small ball inserted into the colon of mice or rats (2 5) . A lag in the evacuation of the ball is known to be caused by the opioid agonist loperamide (5) and by the a2 adrenergic receptor agonist clonidine (4) . In the present study, we examined whether administration of KW-5092 can restore the delayed colonic propulsion induced by loperamide or clonidine in rats by determining the evacu ation time of a teflon ball.
Male Sprague-Dawley rats (Japan SLC Inc., Hamamatsu), weighing 150-220 g, were used for the ex periment. All animals received humane care in compli ance with the "Guiding Principles for the Care and Use of Laboratory Animals" formulated by the Bioethical Com mittee of the Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd. Prior to the experiment, the animals were fasted 18-22 hr but were access to drinking The effects on the delayed colonic propulsion were de termined with a modification of the reported method (5). The animals were orally administered with each drug at a volume of 5 ml/kg; and 30 min later, they were given an s.c. injection of 0.3 mg/kg of loperamide or 0.01 mg/kg of clonidine. These dosages were enough to delay the ball evacuation, the evacuation time being about 6 times longer than that in the control animals in the preliminary examination. One hour after treatment with the test com pound, a teflon ball, 3.17 mm in diameter, was inserted into the distal colon at 3 cm from the anus under light ether anesthesia.
The The effects on the loperamide-induced delay of colonic propulsion are shown in Fig. 1 . The vehicle of each drug had no effect on the evacuation time of the ball (data not shown). Loperamide at a dose of 0.3 mg/kg, s.c.
significantly delayed the ball evacuation (3.0-8.6 times of the normal). KW-5092 (1-30 mg/kg), neostigmine (0.3 -10 mg/kg) and T-1815 (3 -100 mg/kg) improved the loperamide-induced delay of colonic propulsion in dose-dependent manners. The ID50 (the dose producing 50% inhibition) values of KW-5092, neostigmine and T 1815 were 3.6 mg/kg, 0.8 mg/kg and 51.4 mg/kg, respec tively. HSR-803 (1 30 mg/kg) also shortened the delay of ball evacuation; however, it showed no dose-depend ency. Neither cisapride nor AS-4370 produced any im provement of the colonic propulsion at up to 100 mg/kg. The effects on the clonidine-induced delay of colonic propulsion are shown in Fig. 2 . Clonidine at a dose of 0.01 mg/kg also significantly delayed the ball evacuation. KW-5092 (1-30 mg/kg), neostigmine (1-30 mg/kg) and T-1815 (0.3 -10 mg/kg) decreased the clonidine-induced delay of ball evacuation, as was the case with the loper amide-induced delay of colonic propulsion. The ID50 values of KW-5092, neostigmine and T-1815 were 5.5 mg/kg, 3.5 mg/kg and 3.7 mg/kg, respectively. Raniti dine (3 -100 mg/kg) showed an improvement of colonic propulsion; however, a significant improvement of the co lonic propulsion was observed only at a high dose of 100 mg/kg.
HSR-803, which is known to release acetylcholine from cholinergic nerve terminals (6), had a weak effect as com pared with KW-5092 in both the constipation models. Although ranitidine showed improving activity in both the constipation models in dose-dependent manners, it did not attain the 50% effect even at 100 mg/kg. Cisapride and AS-4370 did not cause any significant im provement in the present constipation models. This effect is in accordance with the previous observation that AS 4370 had no effect on the distal alimentary tract (7) .
It has been reported that T-1815, a trimebutine deriver tive, showed improving effects on loperamide (minimum effective dose=1.0 mg/kg, p.o.) and clonidine (mini mum effective dose=0.3 mg/kg, p.o.) induced constipa tion in mice (5) . In the present study, T-1815 showed im proving effects in both the constipation models; however, the minimum effective doses for the loperamide and the clonidine-induced constipation were 100 mg/kg (p.o.) and 1 mg/kg (p.o.), respectively. These discrepancy may be due to differences in the experimental conditions such as the animal species examined and the doses of the agents inducing constipation.
It is known that clonidine inhibits the release of acetyl choline from cholinergic nerve terminals via stimulation of the a2-adrenergic receptor (4). Since clonidine shows suppressive action on the small intestine both in vivo (5) and in vitro (8), clonidine-induced delay of colonic pro pulsion can be regarded as a model of atonic constipation. On the other hand, loperamide shows a tonic effect on the guinea pig colon, resulting in an inhibition of peristalsis (9). Consequently, loperamide-induced delay of colonic propulsion is considered to be a model of spas tic constipation. In the present study, we demonstrated that KW-5092 clearly and dose-dependently improves the loperamide and clonidine-induced delayed colonic propulsion in the rat and that the ID50 values for KW 5092 in the loperamide and clonidine-induced constipa tion were similar (3.6 mg/kg and 5.5 mg/kg, respective ly). The present results suggest that KW-5092 may be use ful for the treatment of patients with constipation of both the atonic and the spastic types. Neostigmine, which is known as an acetylcholine es terase inhibiting agent, showed an improving action 4.5 fold stronger than that of KW-5092 in the loperamide-in duced constipation. On the other hand, it showed similar potency to KW-5092 in the clonidine-induced constipa tion. The difference in the activities of neostigmine and KW-5092 between the clonidine and loperamide-induced models may be due to the difference in the mode of ac tions of these agents. Neostigmine is an established inhibi tor of acetylcholine esterase. In contrast, KW-5092 has not only the acetylcholine esterase inhibitory action (1) but also the ability to induce acetylcholine release from the cholinergic nerve ending (10). Thus, it is likely that the acetylcholine releasing effect of KW-5092 is more in volved in the amelioration of the loperamide-induced con stipation, where the acetylcholine release is intact, than in that of the clonidine-induced constipation, where the acetylcholine release is inhibited.
In summary, the present study demonstrates that KW 5092 improves the delayed propulsion indused by loper amide or clonidine in rats. As KW-5092 has the stimulato ry effect on cholinergic neurons, it is suggested that KW 5092 is useful for the treatment of diseases accompanied with the dysfunction of cholinergic neurons. 
